Short-Term Debt to Capital: centogene.com (CNTG)

Centogene N.V. (CNTG) relies on a high-tech center in Rostock, where process stability is tied to biomaterial logistics. In alliance with major pharmaceutical companies, the business creates analytical datasets to combat orphan pathologies. This chart of the share price on GURU.Markets shows a debt-to-equity ratio of 0.00, while the company maintains pricing power in genetics despite competition in general testing.

This indicator measures the proportion of liabilities maturing within one year relative to equity, revealing the extent of the company's dependence on operational refinancing; amid severe liquidity shortages and the restructuring of Centogene N.V. (CNTG), this parameter becomes a critical marker of solvency, meaning an upward trend in short-term debt-to-equity signals a growing risk of default in the absence of external investment.